Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.65 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368295 | 0.91 | HDAC1 (0.68) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL15512850 | 0.90 | HDAC1 (0.61) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL2073238 | 0.90 | HDAC1 (0.57) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL15513441 | 0.89 | HDAC1 (0.66) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL2368507 | 0.87 | HDAC1 (0.64) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL2073281 | 0.87 | HDAC1 (0.68) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL24145538 | 0.87 | HDAC3 (0.60) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL24146140 | 0.86 | HDAC1 (0.50) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL24146124 | 0.85 | HDAC1 (0.60) | HDAC1HDAC3HDAC6HDAC2HDAC4 | |
| SCHEMBL15513604 | 0.85 | HDAC1 (0.76) | HDAC1HDAC3HDAC6HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC3 7/4885HDAC6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.